Trial Profile
A Phase II Pilot Study to Evaluate the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction. IDA53 Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms IDA53
- 13 Dec 2022 Results of the Filo Phase II Study IDA53 assessing daratumumab would improve ibrutinib efficacy in R/R CLL patients with TP53 aberrations presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 27 Jun 2022 Planned End Date changed from 1 Jun 2027 to 1 Jun 2026.
- 27 Jun 2022 Planned primary completion date changed from 1 Dec 2026 to 1 Jun 2024.